A retrospective study of patients of immune checkpoint inhibitors in patients with preexisting autoimmune diseases (PAD)
Latest Information Update: 18 Aug 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer; Lung cancer; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 18 Aug 2021 New trial record
- 01 Aug 2021 Results published in the Cancer Immunology Immunotherapy.